Business · Markets · 7 hrs ago
HanAll Biopharma shares jump after partner reports rheumatoid arthritis trial efficacy
HanAll Biopharma shares surged early on Nov.
10 on South Korea’s stock market.
The rise followed news that its global partner found efficacy in a clinical trial for difficult-to-treat rheumatoid arthritis.
HanAll is linked to the treatment through a technology-transfer partnership with the partner.
At 9:15 a.m., the shares were up 21.97%, trading at 45,250 won.
The news matters because the trial result points to potential activity against hard-to-treat rheumatoid arthritis.
The available information does not say what the next trial steps will be.
HanAll Biopharma shares rose sharply after news that its licensing partner had found efficacy in a clinical trial for difficult-to-treat rheumatoid arthritis.
At 9:15 a.m. on Nov. 10, the shares were up 21.97% on the Korea Exchange.
The stock was trading at 45,250 won, up 8,150 won from the previous trading day.
The article attributed the buying interest to the trial news.
- Who
- HanAll Biopharma and its global licensing partner.
- What
- HanAll shares surged after news that the partner found efficacy in a clinical trial for difficult-to-treat rheumatoid arthritis.
- When
- Nov. 10, 2026. The share price was reported at 9:15 a.m.
- Where
- The Korea Exchange.
- Why
- Buying interest followed news of efficacy in the rheumatoid arthritis trial.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Date
- Nov. 10, 2026
- Time
- 9:15 a.m.
- Share-price change
- Up 21.97%, or 8,150 won
- Share price
- 45,250 won
- Trial
- Efficacy reported in a trial for difficult-to-treat rheumatoid arthritis